FirstIgnite is supporting the commercialization of Bowling Green State University’s new COVID-19 related technology for DNA aptamers as universal inhibitors of spike protein/hACE2 interactions. The benefits of this technology include that it is cost-effective, has low immunogenicity and toxicity, and can be manufactured using routine chemical synthesis. Additionally, it could bridge the gap for at-risk individuals and young children (ages 2-5) who can’t or shouldn’t take current COVID vaccines or therapies.
As COVID-19 treatments become more prevalent, the market continues to grow. By 2030, $25.6 billion is expected to be generated by the global COVID-19 therapeutics market, which was valued at $5.26 billion in 2020.
Bowling Green State University’s technology for DNA aptamers as universal inhibitors of spike protein/hACE2 interactions is ready for commercialization, and they are looking for industry feedback on their research and potential future collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Bowling Green State University team, you can schedule a time directly on their team’s calendar here.
